The Flow Cytometry Core provides a broad range of applications to Cancer Center Members including the following: light scatter measurements assessing cell volume and structural differences; single and multiple intracellular and/or surface immunofluorescence measurements; DNA ploidy measurements of cellular calcium and potassium flux, and oxidative burst; detection and quantitation of apoptotic cell death; cell sorting on any or a combination of several analytical criteria. The Flow Cytometry Core Facility re-located in the University of Michigan Cancer and Geriatrics Center's building upon completion of the new facility in 1997. Members of the UMCCC (108 users in 1999) constitute a majority of the use of the Core, and the UMCCC provides 39% of the operating budget of the facility ($253,000 in 1999). In return for this support, UWCCC members are eligible for a 50% discounted recharge rate. Individual investigators deliver pre-processed samples to the Core for flow cytometric analyses or cell sorting. Scheduling for Core access typically requires a lead-time of 24 hours notice. The Core is available to investigators from 8:00 AM to 6:00 PM, Monday through Friday, and from 8:00 to 1:00 Saturday. Core instrumentation includes two Beck-Coulter Elite ESP multi-laser cell sorters, a Becton Dickinson FACS Vantage SE multi-laser high-speed cell sorter, and a Coulter EPICS XL analyzer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA046592-14
Application #
6484707
Study Section
Project Start
1988-09-30
Project End
2006-05-31
Budget Start
Budget End
Support Year
14
Fiscal Year
2001
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Manohar, Poorni M; Beesley, Lauren J; Bellile, Emily L et al. (2018) Prognostic Value of FDG-PET/CT Metabolic Parameters in Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer. Clin Nucl Med 43:641-647
Hawley, Sarah T; Li, Yun; An, Lawrence C et al. (2018) Improving Breast Cancer Surgical Treatment Decision Making: The iCanDecide Randomized Clinical Trial. J Clin Oncol 36:659-666
Salami, Simpa S; Hovelson, Daniel H; Kaplan, Jeremy B et al. (2018) Transcriptomic heterogeneity in multifocal prostate cancer. JCI Insight 3:
Smith, Joshua; Kulkarni, Aditi; Birkeland, Andrew C et al. (2018) Whole-Exome Sequencing of Sinonasal Small Cell Carcinoma Arising within a Papillary Schneiderian Carcinoma In Situ. Otolaryngol Head Neck Surg 159:859-865
Eberl, Markus; Mangelberger, Doris; Swanson, Jacob B et al. (2018) Tumor Architecture and Notch Signaling Modulate Drug Response in Basal Cell Carcinoma. Cancer Cell 33:229-243.e4
Lazarus, Jenny; Maj, Tomasz; Smith, J Joshua et al. (2018) Spatial and phenotypic immune profiling of metastatic colon cancer. JCI Insight 3:
Kim, Yeung-Hyen; Zhu, Lingqiao; Pyaram, Kalyani et al. (2018) PLZF-expressing CD4 T cells show the characteristics of terminally differentiated effector memory CD4 T cells in humans. Eur J Immunol 48:1255-1257
Davis, Elizabeth J; Griffith, Kent A; Kim, Edward J et al. (2018) A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers. Am J Clin Oncol 41:128-132
Mendiratta-Lala, Mishal; Masch, William; Shankar, Prasad R et al. (2018) MR Imaging Evaluation of Hepatocellular Carcinoma Treated with Stereotactic Body Radiation Therapy (SBRT): Long Term Imaging Follow-Up. Int J Radiat Oncol Biol Phys :
Tamura, Shuzo; Wang, Yin; Veeneman, Brendan et al. (2018) Molecular Correlates of In Vitro Responses to Dacomitinib and Afatinib in Bladder Cancer. Bladder Cancer 4:77-90

Showing the most recent 10 out of 1493 publications